Compare Cytokinetics Inc (CYTK) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Corning Incorporated — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Corning Incorporated trades at $157.7 (market cap $131.65B). The key difference: Corning Incorporated is far larger — about 15.3× Cytokinetics Inc's market cap, and Corning Incorporated pays a 0.73% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Corning Incorporated for 35 Days on average.
| CYTK | GLW | |
|---|---|---|
Market Cap | $8.62B | $131.65B |
Volume | 2,594,626 | 8,992,522 |
Sector | Health | Technology |
52-Week High | $87.26 | $255.79 |
52-Week Low | $54.76 | $78.03 |
Typical Hold Time | 19 Days | 35 Days |
Enterprise Value | $8.72B | $138.52B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
GLW trades at $163.21, down 3.41% today, with a bullish technical signal and strong analyst support (56.75% buy ratings). Recent fundamentals show robust revenue growth to $15.63B in 2025 and net income of $1.60B, though valuation ratios like P/E of 70.43 appear elevated. The company secured a significant $3B+ fiber supply deal with AT&T, driving positive sentiment amid AI infrastructure demand.
Outlook is positive with earnings beats and a consensus price target of $171.25 offering ~5% upside. Key risks include high debt levels, patent litigation, and sensitivity to tech spending cycles. Institutional confidence remains high given operational cash flow strength and strategic positioning in fiber optics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
